Have You Marked Your Calendar For DURECT?

Clinical trial results are major catalysts for biotech/pharma companies. Today, we bring to your attention a biopharma stock, which soared 49% on Friday in the run-up to reporting alcoholic hepatitis trial results - DURECT Corporation (DRRX).

from RTT - Biotech http://bit.ly/2Y2nqqS
via IFTTT